Physician profile
John B Chawluk
NPI 1376548594
$265,147.58
in general payments reported to CMS, 2019-2025
56 companies · $441 in 2025
The $441 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $44K · 2021: $89K · 2022: $66K · 2023: $30K · 2024: $9,306 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $4,668 · Travel and Lodging: $4,277 · Consulting Fee: $1,800 · Education: $57.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,031.50 |
| Food and Beverage | $4,667.78 |
| Travel and Lodging | $4,276.97 |
| Consulting Fee | $1,800.00 |
| Education | $57.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $64,852.22 | 2019-2024 | Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $61,033.98 | 2020-2021 | |
| Abbvie INC. | $46,330.75 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Biohaven Pharmaceutical Holding Company LTD. | $44,597.11 | 2022 | |
| Allergan, INC. | $21,384.88 | 2019-2021 | |
| Emd Serono, INC. | $17,650.64 | 2019-2025 | Mavenclad, Mavenclad |
| Abbott Laboratories | $3,101.71 | 2019-2023 | Infinity |
| Livanova USA, INC. | $972.01 | 2022-2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Eisai INC. | $439.88 | 2019-2024 | |
| Medtronic, INC. | $350.98 | 2021-2025 | Percept PC Brainsense, Sensight |
| Novartis Pharmaceuticals Corporation | $289.39 | 2019-2024 | |
| Sk Life Science, INC. | $286.08 | 2020-2024 | |
| Amneal Pharmaceuticals LLC | $275.63 | 2019-2025 | Rytary, Ongentys, Lyvispah |
| Alexion Pharmaceuticals, INC. | $259.79 | 2019-2024 | Ultomiris |
| Genzyme Corporation | $209.04 | 2019-2022 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $206.59 | 2019-2024 | Apokyn |
| Biogen, INC. | $168.71 | 2019-2024 | Vumerity, Tysabri, Plegridy |
| Acadia Pharmaceuticals INC | $165.12 | 2019-2024 | Nuplazid |
| Ucb, INC. | $160.01 | 2022-2024 | Fintepla, Rystiggo |
| Celgene Corporation | $151.10 | 2020-2024 | Zeposia |
| Sunovion Pharmaceuticals INC. | $142.10 | 2019-2022 | |
| Csl Behring | $132.86 | 2019-2024 | Hizentra |
| E.R. Squibb & Sons, L.L.C. | $132.12 | 2020-2021 | |
| Pfizer INC. | $130.14 | 2019-2024 | |
| Neurocrine Biosciences, INC. | $125.70 | 2019-2024 | Ingrezza, Ongentys |
| Lundbeck LLC | $124.84 | 2019-2024 | Vyepti |
| Genentech USA, INC. | $105.29 | 2019-2024 | Enspryng, Ocrevus |
| Amgen INC. | $101.29 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $87.39 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $86.59 | 2019-2020 | |
| Axsome Therapeutics, INC. | $82.59 | 2023-2024 | Sunosi |
| Neurelis, INC. | $80.51 | 2022-2024 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $72.66 | 2023-2024 | Nuedexta, Rexulti |
| Greenwich Biosciences, INC. | $70.24 | 2019-2021 | |
| Lilly USA, LLC | $69.46 | 2019-2024 | Amyvid |
| Catalyst Pharmaceuticals, INC. | $66.77 | 2019-2024 | |
| Kyowa Kirin, INC. | $66.65 | 2019-2024 | Nourianz |
| Tg Therapeutics, INC. | $64.14 | 2023-2024 | |
| Acorda Therapeutics, INC | $57.01 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $53.48 | 2019-2020 | |
| Argenx US, INC. | $52.14 | 2022-2024 | Vyvgart |
| Harmony Biosciences LLC | $49.33 | 2022-2023 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $39.55 | 2019 | |
| Jazz Pharmaceuticals INC. | $37.72 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $31.73 | 2019-2022 | |
| Assertio Therapeutics, INC. | $30.69 | 2019 | |
| Impel Pharmaceuticals INC. | $22.83 | 2023 | Trudhesa |
| Xeris Pharmaceuticals, INC. | $21.17 | 2024 | Keveyis |
| Life Molecular Imaging LTD | $18.57 | 2023 | Neuraceq |
| Sandoz INC. | $17.53 | 2024 | Zarxio |
| Tanabe Pharma America, INC. | $17.18 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.53 | 2019 | |
| Ani Pharmaceuticals, INC. | $15.88 | 2023 | Purified Cortrophin Gel |
| Medtronic USA, INC. | $14.66 | 2020 | |
| Mallinckrodt Hospital Products INC. | $13.30 | 2020 | |
| Mallinckrodt Enterprises LLC | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Chawluk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.